Levi & Korsinsky, LLP has filed a class action lawsuit against Regeneron Pharmaceuticals for allegedly providing false and misleading information about its Phase III Fianlimab-Libtayo study. The complaint claims Regeneron concealed that the trial was failing to meet key clinical endpoints, leading to a sharp stock price decline after disclosures in April and May 2026. Investors who suffered losses can seek lead plaintiff status by September 14, 2026. The lawsuit aims to recover losses caused by these alleged misrepresentations.
Levi & Korsinsky, LLP has filed a class action lawsuit against Regeneron Pharmaceuticals, alleging the company misled investors about its Phase III Fianlimab-Libtayo study results. The complaint claims Regeneron made false positive statements while c...
In Q2 2026, Baird's Chautauqua International Growth Fund returned +10.39%, trailing the MSCI ACWI ex-U.S. Index's +14.49%. Key detractors included Alibaba and Lululemon, while Recruit and ASML contributed positively. The Global Growth Fund also lagge...
